Literature DB >> 24125777

Murine xenogeneic models of myelodysplastic syndrome: an essential role for stroma cells.

Xiang Li1, H Joachim Deeg2.   

Abstract

The objective of is this article is to review murine xenotransplantation models for myelodysplastic syndromes (MDS). The difficulties in achieving sustained engraftment of MDS cells in immunodeficient mice may lie in innate characteristics of the MDS clones and microenvironmental factors. Engraftment of very low numbers of CD45(+) clonal MDS cells has been achieved with intravenous injection; higher rates of engraftment are obtained via the intramedullary route. Coinjection of certain stroma components with hematopoietic cells overcomes limitations of intravenous (IV) administration, allowing for engraftment of high proportions of human CD45(+) cells in mouse spleen and marrow. Expression of CD146 on stroma cells conveys an engraftment-facilitating effect. Clonal MDS cells have been propagated for periods beyond 6 months and have been transplanted successfully into secondary recipients. Engraftment of human clonal MDS cells with stem cell characteristics in immunodeficient mice is greatly facilitated by coinjection of stroma/mesenchymal cells, particularly with IV administration. CD146 expression on stroma is an essential factor; however, no model develops the laboratory and clinical features of human MDS. Additional work is needed to determine cellular and noncellular factors required for the full evolution of MDS.
Copyright © 2014 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24125777      PMCID: PMC4053244          DOI: 10.1016/j.exphem.2013.10.002

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  66 in total

1.  A perivascular origin for mesenchymal stem cells in multiple human organs.

Authors:  Mihaela Crisan; Solomon Yap; Louis Casteilla; Chien-Wen Chen; Mirko Corselli; Tea Soon Park; Gabriella Andriolo; Bin Sun; Bo Zheng; Li Zhang; Cyrille Norotte; Pang-Ning Teng; Jeremy Traas; Rebecca Schugar; Bridget M Deasy; Stephen Badylak; Hans-Jörg Buhring; Jean-Paul Giacobino; Lorenza Lazzari; Johnny Huard; Bruno Péault
Journal:  Cell Stem Cell       Date:  2008-09-11       Impact factor: 24.633

2.  Role of nucleophosmin in embryonic development and tumorigenesis.

Authors:  Silvia Grisendi; Rosa Bernardi; Marco Rossi; Ke Cheng; Luipa Khandker; Katia Manova; Pier Paolo Pandolfi
Journal:  Nature       Date:  2005-07-06       Impact factor: 49.962

3.  Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level.

Authors:  L Nilsson; I Astrand-Grundström; I Arvidsson; B Jacobsson; E Hellström-Lindberg; R Hast; S E Jacobsen
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

4.  The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes.

Authors:  Xiang Li; A Mario Marcondes; Theodore A Gooley; H Joachim Deeg
Journal:  Blood       Date:  2010-06-18       Impact factor: 22.113

Review 5.  Myelodysplastic syndromes: an update on molecular pathology.

Authors:  Mar Tormo; Isabel Marugán; Marisa Calabuig
Journal:  Clin Transl Oncol       Date:  2010-10       Impact factor: 3.405

6.  Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins.

Authors:  M Konopleva; S Konoplev; W Hu; A Y Zaritskey; B V Afanasiev; M Andreeff
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

Review 7.  CD146, a multi-functional molecule beyond adhesion.

Authors:  Zhaoqing Wang; Xiyun Yan
Journal:  Cancer Lett       Date:  2012-12-21       Impact factor: 8.679

8.  Active Notch1 confers a transformed phenotype to primary human melanocytes.

Authors:  Chelsea C Pinnix; John T Lee; Zhao-Jun Liu; Ronan McDaid; Klara Balint; Levi J Beverly; Patricia A Brafford; Min Xiao; Benjamin Himes; Susan E Zabierowski; Yumi Yashiro-Ohtani; Katherine L Nathanson; Ana Bengston; Pamela M Pollock; Ashani T Weeraratna; Brian J Nickoloff; Warren S Pear; Anthony J Capobianco; Meenhard Herlyn
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

9.  Myelodysplastic syndromes: incidence and survival in the United States.

Authors:  Xiaomei Ma; Monique Does; Azra Raza; Susan T Mayne
Journal:  Cancer       Date:  2007-04-15       Impact factor: 6.860

10.  Effect of intravenous coadministration of human stroma cell lines on engraftment of long-term repopulating clonal myelodysplastic syndrome cells in immunodeficient mice.

Authors:  X Li; A M Marcondes; T Ragoczy; A Telling; H J Deeg
Journal:  Blood Cancer J       Date:  2013-04-26       Impact factor: 11.037

View more
  11 in total

Review 1.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

2.  Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients.

Authors:  S Jilg; V Reidel; C Müller-Thomas; J König; J Schauwecker; U Höckendorf; C Huberle; O Gorka; B Schmidt; R Burgkart; J Ruland; H-J Kolb; C Peschel; R A J Oostendorp; K S Götze; P J Jost
Journal:  Leukemia       Date:  2015-07-08       Impact factor: 11.528

Review 3.  The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression.

Authors:  Allison J Li; Laura M Calvi
Journal:  Exp Hematol       Date:  2017-08-18       Impact factor: 3.084

Review 4.  Biology of BM failure syndromes: role of microenvironment and niches.

Authors:  Sophia R Balderman; Laura M Calvi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18

Review 5.  Biology of the bone marrow microenvironment and myelodysplastic syndromes.

Authors:  Erinn B Rankin; Anupama Narla; Joseph K Park; Shuo Lin; Kathleen M Sakamoto
Journal:  Mol Genet Metab       Date:  2015-07-20       Impact factor: 4.797

Review 6.  Myelodysplasia is in the niche: novel concepts and emerging therapies.

Authors:  E Bulycheva; M Rauner; H Medyouf; I Theurl; M Bornhäuser; L C Hofbauer; U Platzbecker
Journal:  Leukemia       Date:  2014-11-14       Impact factor: 11.528

Review 7.  Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?

Authors:  Lisa Pleyer; Peter Valent; Richard Greil
Journal:  Int J Mol Sci       Date:  2016-06-27       Impact factor: 5.923

8.  Preclinical modeling of myelodysplastic syndromes.

Authors:  K Rouault-Pierre; S A Mian; M Goulard; A Abarrategi; A Di Tulio; A E Smith; A Mohamedali; S Best; A-M Nloga; A G Kulasekararaj; L Ades; C Chomienne; P Fenaux; C Dosquet; G J Mufti; D Bonnet
Journal:  Leukemia       Date:  2017-06-02       Impact factor: 11.528

9.  Screening differentially expressed proteins from co-cultured hematopoietic cells and bone marrow-derived stromal cells by quantitative proteomics (SILAC) method.

Authors:  Rui Liu; Yi Wang; Bingxin Li; Hui Wang; Feng Guan; Zengqi Tan; Xiang Li
Journal:  Clin Proteomics       Date:  2019-07-18       Impact factor: 3.988

10.  The functional interplay of transcription factors and cell adhesion molecules in experimental myelodysplasia including hematopoietic stem progenitor compartment.

Authors:  Suchismita Daw; Sujata Law
Journal:  Mol Cell Biochem       Date:  2020-10-04       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.